| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.098 | 0.04 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.092 | 0.05 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.37 | 0.05 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.059 | 0.05 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.06 |